PharmaFocus Today – Page 173 – media

1 “Parkinson’s new drug” approved for marketing

According to the official website of NMPA, Zambon/Parexel Pharmaceuticals’ Safinamide Mesylate Tablets have been approved for marketing. According to public information, Safinamide is a drug used to treat Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disease and a common activity disorder. Its main cause is a lack of dopamine. According to statistics, about 1-2% of people over 65 years old suffer from Parkinson’s disease worldwide. In China, there are more than 3 million Parkinson’s disease patients, and the incidence rate increases with age. It is predicted that the number of Parkinson’s patients in China will exceed 5 million in 2030. The “OFF” period is a common phenomenon in the middle and late stages of Parkinson’s disease. Patients usually show severe aggravation of symptoms such as muscle stiffness, tremor and movement difficulties. According to statistics, about 75% of Parkinson’s patients in the middle and late stages will ...
- Source: https://news.yaozh.com/archive/44631.html
- 437
- December 7, 2024
A local pharmaceutical company’s road to overtaking on a curve

At the end of 2011, the first drug of ranibizumab entered the Chinese market. As a biological drug for the treatment of fundus macular degeneration, it has a monopoly advantage in the market and is priced at nearly 10,000 yuan per bottle. Originally, multinational pharmaceutical companies wanted to make a fortune from this star product in the huge Chinese market, but no one could have imagined that a Chinese local company that “sticks to its research and development” – Kanghong Pharmaceutical would overtake others and bring down the price of the drug in one fell swoop… A pioneering journey of “a narrow escape from death” In 1994, Kanghong was established in the wave of reform and opening up. This innovative pharmaceutical company started with traditional Chinese medicine. Its Songling Xuemaikang Capsule is an exclusive patented Chinese medicine for the treatment of hypertension and primary hyperlipidemia. At the same time, in ...
- Source: https://news.yaozh.com/archive/44633.html
- 595
- December 7, 2024
Siemens Healthineers collaborates with the ‘Third Party Imaging Leader’

On December 1st, Siemens Healthineers and DeepHealth officially announced a major strategic partnership, with the latter partnering with Siemens Healthineers to implement SmartTechnology by embedding AI driven health informatics into workflows and imaging hardware ™， Bringing innovative changes to the field of ultrasound operations. Data shows that DeepHealth is a wholly-owned subsidiary of RadNet, a global leader in AI driven health informatics, dedicated to providing AI driven health informatics to achieve breakthroughs in the nursing field through imaging. RadNet is also the largest third-party independent medical imaging company in the United States. 01. DeepHealth collaborates with Siemens Healthineers At present, the high-capacity ultrasound nursing environment is facing severe challenges such as labor shortage, operator limitations and fatigue, and unstable image acquisition quality. These problems may not only delay accurate diagnosis, but also lead to unnecessary examination processes. In response to this situation, the remote collaboration and image acquisition command center ...
- Source: drugdu
- 327
- December 6, 2024
Toshiba to lay off another 3000 employees

Recently, according to authoritative financial media such as Kyodo News, legendary giant Toshiba is planning to implement a large-scale layoff in Japan, with an expected number of layoffs exceeding 3000, accounting for about 5% of its total Japanese employees. Toshiba further stated that this round of layoffs will mainly target employees aged 50 and above, and will be carried out through voluntary resignation. For employees who choose to resign before the end of November this year, the company will provide additional severance pay and promise to provide a two-year re employment support service to alleviate their worries. It is worth noting that this is not the first time Toshiba has taken large-scale layoffs this year. As early as May this year, Toshiba announced that it would lay off up to 5000 employees in Japan, accounting for about 6%, with the aim of accelerating the restructuring process and reducing costs to ...
- Source: drugdu
- 227
- December 6, 2024
Oncology field blossoms

On November 27, Huadong Medicine announced that its Sometuximab Injection and Rilonacept for Injection were approved for marketing by NMPA. On the same day, the drug registration and marketing authorization application for CD19 CAR-T candidate IM19 chimeric antigen receptor T cell injection (hereinafter referred to as “IM19”) was also accepted by NMPA. Sometuximab Injection (ELAHERE®/ELAHERE®) is used for the indication of folate receptor α-positive platinum-resistant ovarian cancer (PROC) that has received 1-3 lines of systemic treatment in the past; Rilonacept for Injection (trade name: Yanduo®/ARCALYST®) is used to treat cold pyrine-associated periodic syndrome (CAPS) in adults and adolescents aged 12 years and above, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). Suomitoximab is a drug targeting FRα targets and is the only platinum-resistant recurrent ovarian cancer treatment drug on the market in the world. According to public information, Suomitoximab can recognize target proteins on the surface of tumor ...
- Source: drugdu
- 205
- December 6, 2024
Novo Nordisk’s “GIP/GLP-1 dual agonist” has been approved for clinical trials in China

According to the CDE official website, Novo Nordisk’s Class 1 new drug NNC0519-0130 injection has obtained implicit approval for clinical trials, and its indication is type 2 diabetes. According to public information, the drug is a GIP/GLP-1 dual agonist. GIP and GLP-1 are two important hormones that regulate blood sugar. The function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion; GIP is a dual-function hormone that promotes insulin secretion in high blood sugar and stimulates the release of glucagon in low blood sugar to stabilize blood sugar. Studies have shown that GIP can reduce food intake and increase energy consumption, thereby reducing weight. When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on glucose levels and body weight. According to the ClinicalTrials website, Novo Nordisk has launched multiple clinical studies on NNC0519-0130 injection in many places around the world, including ...
- Source: drugdu
- 296
- December 6, 2024
Employee sentenced to 13 years in prison, AstraZeneca insurance fraud storm is not over

From June to September 2024, many cases related to AstraZeneca insurance fraud were sentenced one after another. An operation named “Star Project” by the prosecutor revealed the tip of the iceberg of pharmaceutical representatives tampering with genetic test reports and defrauding medical insurance funds. AstraZeneca, the fastest growing British multinational pharmaceutical company in China and the most watched “sales champion” in the pharmaceutical industry, was exposed to be involved in many “insurance fraud cases”. According to the criminal verdicts obtained by the reporter, in the past three years, there have been many AstraZeneca “insurance fraud cases” that have been tried or sentenced in Shenzhen and Fujian alone, and there are also cases waiting to be heard in Chongqing and Jiangxi. Some people in the pharmaceutical industry pointed out that the AstraZeneca insurance fraud case can be said to be the most shocking event caused by multinational pharmaceutical companies in China ...
- Source: drugdu
- 201
- December 6, 2024
“China’s Multi-Antibody Star” launches IPO

Recently, “China’s multi-antibody star” Welly Zhibo Biotech submitted a prospectus to the Hong Kong Stock Exchange, intending to go public on the main board of Hong Kong through an IPO. This biotech, founded in 2012, had just completed a large NewCo-style BD and also completed a C+ round of financing in November. The latest post-investment valuation has exceeded 3 billion yuan. The latest valuation is over 3 billion. Welly Zhibo’s CEO is Dr. Kang Xiaoqiang, who studied for his master’s degree at Tongji Medical College, and completed his doctoral and postdoctoral studies in the United States. Later, he joined a biotech called ImClone Systems, which became famous for the development of the EGFR monoclonal antibody Erbitux. The drug was launched in 2004, with peak sales of more than 2 billion US dollars, and Kangbo participated in the development and launch of the drug. In 2008, ImClone Systems was acquired by ...
- Source: drugdu
- 428
- December 6, 2024
Sanofi will build a new insulin production base in Beijing

On December 2nd, Beijing welcomed an investment of up to 1 billion euros (approximately 7.66 billion yuan) – the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Economic and Technological Development Zone Management Committee, and multinational pharmaceutical company Sanofi signed a memorandum of cooperation. Sanofi will build a new insulin production base in Yizhuang, and after completion, it will form a full industry chain layout of insulin preparations from raw materials to finished products in Beijing. Sanofi will invest in the construction of the second Beijing production base, improve the local end-to-end production and manufacturing capacity of insulin, and focus on serving the insulin drug demand of local diabetes patients. This will be Sanofi’s fourth production and supply base in China, and also the company’s largest single investment in China. Over the past 40 years of deep cultivation in China, Sanofi has continuously increased its investment in Chinese ...
- Source: drugdu
- 417
- December 5, 2024
Over 1 billion US dollars! Yingen Biotech Innovates Preclinical ADC Drug Authorization GSK

Today (December 4, 2024), Duality Biologics announced that it has reached an exclusive licensing agreement with GlaxoSmithKline (GSK) for an antibody conjugated drug (ADC) DB-1324. According to the agreement, GSK will obtain the exclusive authorization of the world (excluding Chinese Mainland, Hong Kong and Macao) to promote the development and commercialization of the ADC drug. According to the terms of the agreement, GSK will pay $30 million in advance and other pre exercise milestone payments to obtain an exclusive license to promote the R&D and commercialization of DB-1324 worldwide (excluding Chinese Mainland, Hong Kong and Macao). If GSK exercises its licensing rights, Yingen Biotechnology will charge an exercise fee and subsequent milestone payments at different stages of development, regulatory registration, and commercialization, up to a maximum of $975 million. After successful commercialization, GSK will pay different proportions of graded royalties to the global net sales (excluding Chinese Mainland, Hong Kong ...
- Source: drugdu
- 437
- December 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.